Yttrium-90 citrate colloid for radioisotope synovectomy

Area of Science:

• Radiochemistry
• Nuclear Medicine
• Materials Science

Background:

• Synovial membrane inflammation is a common cause of joint pain.
• Targeted radiotherapy offers a localized treatment approach.
• Yttrium-90 (90Y) is a beta-emitting radioisotope suitable for brachytherapy.

Purpose of the Study:

• To describe the preparation of a yttrium-90 citrate colloid.
• To evaluate the intra-articular retention of the 90Y colloid.
• To assess the safety and efficacy of this formulation for treating synovial membrane conditions.

Main Methods:

• Yttrium-90 (90Y) was eluted from strontium-90 (90Sr) using a sulfonic acid ion exchange resin.
• A 3:1 ratio of carrier yttrium to citrate was used for colloid preparation.
• Radiochemical purity and contamination levels (ionic 90Y and 90Sr) were quantified.

Main Results:

• The yttrium-90 citrate colloid preparation was successfully achieved with low contamination (<1% ionic 90Y, <0.001% ionic 90Sr).
• In 28 patients, the injected 90Y dose remained confined to the joint region, demonstrating excellent intra-articular localization.
• Brief clinical outcomes indicate potential therapeutic benefit.

Conclusions:

• Yttrium-90 citrate colloid is a promising agent for intra-articular radiotherapy.
• The formulation's ability to localize in the synovial membrane minimizes extra-articular radiation.
• Further clinical studies are warranted to establish its therapeutic role.